Rosuvastatin/Ezetimibe and Cyclosporine Interaction

Understanding the Rosuvastatin/Ezetimibe and Cyclosporine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Rosuvastatin/Ezetimibe belongs to the Statin / Cholesterol Absorption Inhibitor class and Cyclosporine belongs to the Calcineurin Inhibitor (Immunosuppressant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cyclosporine causes rosuvastatin levels to rise significantly, which increases the danger of severe muscle damage. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Rosuvastatin/Ezetimibe has 12 total documented interactions on file in this dataset, and Cyclosporine has 89. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination increases the risk of muscle breakdown, so your doctor may need to adjust your treatment or avoid using them together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rosuvastatin/Ezetimibe or Cyclosporine based on a web page, speak with your prescriber or pharmacist before making any change.